SLXN

Silexion Therapeutics Corp (SLXN) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Silexion Therapeutics Corp is a clinical-stage biotechnology company focused on developing RNAi therapeutics to silence the KRAS oncogene, primarily for pancreatic cancer. The company operates as a single segment and is currently in a development stage with no product revenue. The financial statements reflect the combined entity following a business combination with Moringa Acquisition Corp completed in August 2024.

Key Financial Metrics

Note: All share data has been retroactively adjusted for 1-for-9 and 1-for-15 reverse share splits.

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased significantly by 72.3% in Q3 2025 compared to Q3 2024, and by 49.3% on a year-to-date basis. This improvement is primarily driven by a substantial reduction in non-cash share-based compensation expenses and the absence of one-time transaction costs associated with the August 2024 business combination.
• Expense Composition: While total operating expenses decreased, cash-based costs for subcontractors and consultants increased in Q3 2025 due to progression in API manufacturing and formulation development for the lead candidate, SIL204.
• Liquidity Improvement: Cash and cash equivalents increased from $2.0 million at the end of Q3 2024 to $9.2 million at the end of Q3 2025, bolstered by successful equity financings.

Guidance, Outlook, and Risks

• Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the filing date. Current cash is estimated to fund operations only until the end of Q2 2026.
• Financing Activities: The company raised approximately $11.0 million in gross proceeds from public offerings in January and September 2025, plus additional proceeds from warrant exercises and inducement transactions. An At-The-Market (ATM) facility for up to $13.2 million was established in September 2025 but has not yet been utilized due to standstill restrictions.
• Nasdaq Compliance: The company successfully remedied deficiencies regarding minimum bid price (via a 1-for-15 reverse split) and shareholders' equity requirements. It remains subject to a mandatory panel monitor until September 2026.
• Legal Contingency: The Moringa Sponsor has disputed the conversion of $1.8 million of the A&R Sponsor Promissory Note into ordinary shares during the September offering and has demanded full repayment. The company maintains the conversion was compliant with the note's terms.
• Geopolitical Risk: The company notes ongoing hostilities in the Middle East but states the impact on operations and financial condition remains immaterial as of the reporting date.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "substantial doubt" assessment and the specific timeline for cash depletion (estimated end of Q2 2026).
• Financing Capacity: Confirm the status of the ATM facility and the ability to execute future equity raises without excessive dilution, given the high number of outstanding warrants.
• Legal Dispute: Monitor the status of the dispute with the Moringa Sponsor regarding the promissory note conversion and potential cash outflow requirements.
• Listing Status: Track compliance with Nasdaq Capital Market requirements, specifically the $2.5 million shareholders' equity threshold, throughout the monitoring period.
• R&D Milestones: Assess progress on SIL204 toxicological studies and the timeline for initiating clinical trials, which are contingent on regulatory clearance.